- Home
- IPHA vs GLDG Comparison
IPHA vs GLDG Comparison
Compare IPHA & GLDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- GLDG
- Stock Information
- Founded
- IPHA 1999
- GLDG 2009
- Country
- IPHA France
- GLDG Canada
- Employees
- IPHA N/A
- GLDG N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- GLDG Precious Metals
- Sector
- IPHA Health Care
- GLDG Basic Materials
- Exchange
- IPHA Nasdaq
- GLDG Nasdaq
- Market Cap
- IPHA 187.0M
- GLDG 173.2M
- IPO Year
- IPHA 2019
- GLDG N/A
- Fundamental
- Price
- IPHA $2.30
- GLDG $0.90
- Analyst Decision
- IPHA Strong Buy
- GLDG Strong Buy
- Analyst Count
- IPHA 1
- GLDG 1
- Target Price
- IPHA $11.50
- GLDG $5.25
- AVG Volume (30 Days)
- IPHA 5.6K
- GLDG 583.5K
- Earning Date
- IPHA 09-12-2024
- GLDG 10-11-2024
- Dividend Yield
- IPHA N/A
- GLDG N/A
- EPS Growth
- IPHA N/A
- GLDG N/A
- EPS
- IPHA N/A
- GLDG N/A
- Revenue
- IPHA $68,134,188.00
- GLDG N/A
- Revenue This Year
- IPHA N/A
- GLDG N/A
- Revenue Next Year
- IPHA $105.84
- GLDG N/A
- P/E Ratio
- IPHA N/A
- GLDG N/A
- Revenue Growth
- IPHA 6.88
- GLDG N/A
- 52 Week Low
- IPHA $1.81
- GLDG $0.75
- 52 Week High
- IPHA $3.15
- GLDG $1.08
- Technical
- Relative Strength Index (RSI)
- IPHA 52.64
- GLDG 57.45
- Support Level
- IPHA $2.14
- GLDG $0.83
- Resistance Level
- IPHA $2.35
- GLDG $0.96
- Average True Range (ATR)
- IPHA 0.15
- GLDG 0.04
- MACD
- IPHA 0.00
- GLDG 0.01
- Stochastic Oscillator
- IPHA 58.82
- GLDG 53.85
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About GLDG GoldMining Inc.
GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. The principal projects are its La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia, Crucero project, located in Peru, Sao Jorge, Batistao, Boa Vista, located in Brazil, Yellowknife Gold Project, located in the Northwest Territories, Canada, and other projects. The company earns maximum revenue from Canada.